Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), today announced that, following a review of the Company’s preclinical and clinical data, study design, and manufacturing process, Greece’s National Organization of Medicines has authorized the expansion of the Company’s Phase II trial of Allocetra.
December 7, 2021
· 5 min read